

AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1. (Previously presented) A method for activating T cells, *in vivo*, comprising contacting T cells independent of antigen with a combination of interleukin-2, interleukin-6, and tumor necrosis factor alpha, or functionally equivalent fragments thereof.
2. (Cancelled)
3. (Previously presented) The method of claim 1, wherein the T cells are naive T cells and/or memory resting T cells.
4. (Previously presented) The method of claim 1, wherein the T cells are naive CD45RA+ cells and/or memory resting CD45RO+ cells.
- 5-9. (Cancelled)
10. (Previously presented) The method of any of the preceding claims, wherein the activation of the T cells *in vivo* leads to an enhanced immunological response.
11. (Previously presented) A method of therapy comprising activating in a human or animal subject T cells using the method of claim 10.
12. (Cancelled)